Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2146 to 2160 of 8976 results

  1. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

  2. Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [ID1259]

    In development Reference number: GID-TA10225 Expected publication date: TBC

  3. NY-ESO-1 T-cells for treating synovial sarcoma [ID1286]

    In development Reference number: GID-TA10205 Expected publication date: TBC

  4. Managing common infections - antimicrobial prescribing guidelines

    In development Reference number: GID-NG10050 Expected publication date: TBC

  5. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

  6. Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

    In development Reference number: GID-TA10024 Expected publication date:  28 June 2017

  7. Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]

    In development Reference number: GID-TA11743 Expected publication date: TBC

  8. Dasiglucagon for treating severe hypoglycaemia caused by type 1 diabetes in people under 6 years [TSID12255]

    Topic prioritisation

  9. Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]

    Topic prioritisation

  10. Cyanoacrylate glue for hernia mesh fixation (MT707)

    Topic prioritisation

  11. iQoro neuromuscular training device, (MT809)

    Topic prioritisation

  12. Cyanoacrylate glue for hernia mesh fixation

    Topic prioritisation

  13. eXroid for internal haemorrhoids

    Topic prioritisation

  14. Surgical mesh for treatment of primary ventral hernias

    In development Reference number: GID-HTE10080 Expected publication date:  03 February 2027

  15. Insulin efsitora alfa for treating type 2 diabetes [ID6499]

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026